From Washington: A new drug for pancreatic cancer has been approved by the Food and Drug Administration. The drug, called daraxonrasib, is a first-of-its-kind pill that blocks a mutated protein fueling tumor growth in most pancreatic cancer cases. It will be sold under the brand name Rasonque by Revolution Medicines.

Patients who took the drug in a study nearly doubled their survival time and experienced fewer severe side effects compared to those who received chemotherapy. The study involved 500 patients.

Further details about the drug and its approval are available from the source.